These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 23328596)

  • 1. [Chinese HER2 positive early breast cancer trastuzumab adjuvant therapy: preliminary outcomes].
    Zhang P; Yu SY; Shen ZZ; Song ST; Guan ZZ; Jiao SC; Zheng S; Xu GW; Feng FY
    Zhonghua Yi Xue Za Zhi; 2012 Dec; 92(47):3345-9. PubMed ID: 23328596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: a multicenter cohort analysis.
    Tarantini L; Gori S; Faggiano P; Pulignano G; Simoncini E; Tuccia F; Ceccherini R; Bovelli D; Lestuzzi C; Cioffi G;
    Ann Oncol; 2012 Dec; 23(12):3058-3063. PubMed ID: 22700991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of safety and tolerability of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: Results of an open-label, randomized, multicenter, phase IIIB ESCAPE trial.
    Kaidarova D; Zhavrid E; Shatkovskaya O; Prokharau A; Akhmed N; Sembayev D; Rutzhanova Z; Ivankov A
    Cancer Treat Res Commun; 2024; 40():100817. PubMed ID: 38735220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early Trastuzumab Interruption and Recurrence-Free Survival in ERBB2-Positive Breast Cancer.
    Copeland-Halperin RS; Al-Sadawi M; Patil S; Liu JE; Steingart RM; Dang CT; Yu AF
    JAMA Oncol; 2020 Dec; 6(12):1971-1972. PubMed ID: 33057570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab: Weighing the Benefits and the Risks.
    Blaes AH; Dang C
    J Natl Cancer Inst; 2020 Dec; 112(12):1181-1182. PubMed ID: 32343773
    [No Abstract]   [Full Text] [Related]  

  • 6. A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer.
    Diaby V; Tawk R; Sanogo V; Xiao H; Montero AJ
    Breast Cancer Res Treat; 2015 May; 151(1):27-40. PubMed ID: 25893588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of molecular targeted therapies in lung cancers].
    Suda K; Mitsudomi T
    Nihon Geka Gakkai Zasshi; 2014 May; 115(3):130-6. PubMed ID: 24946519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surface markers of hepatocellular cancer stem cells and their clinical potential.
    Feng D; Wang N; Hu J; Li W
    Neoplasma; 2014; 61(5):505-13. PubMed ID: 24712843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of a pegaspargase-based regimen in the treatment of newly-diagnosed extranodal natural killer/T-cell lymphoma.
    Li L; Zhang C; Zhang L; Li X; Wu JJ; Sun ZC; Fu XR; Wang XH; Chang Y; Wang R; Qiu YJ; Zhang MZ
    Neoplasma; 2014; 61(2):225-32. PubMed ID: 24299319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198).
    Schneider BP; O'Neill A; Shen F; Sledge GW; Thor AD; Kahanic SP; Zander PJ; Davidson NE
    Br J Cancer; 2015 Dec; 113(12):1651-7. PubMed ID: 26625004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.
    Goldhirsch A; Gelber RD; Piccart-Gebhart MJ; de Azambuja E; Procter M; Suter TM; Jackisch C; Cameron D; Weber HA; Heinzmann D; Dal Lago L; McFadden E; Dowsett M; Untch M; Gianni L; Bell R; Köhne CH; Vindevoghel A; Andersson M; Brunt AM; Otero-Reyes D; Song S; Smith I; Leyland-Jones B; Baselga J;
    Lancet; 2013 Sep; 382(9897):1021-8. PubMed ID: 23871490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study.
    Au HJ; Eiermann W; Robert NJ; Pienkowski T; Crown J; Martin M; Pawlicki M; Chan A; Mackey J; Glaspy J; Pintér T; Liu MC; Fornander T; Sehdev S; Ferrero JM; Bée V; Santana MJ; Miller DP; Lalla D; Slamon DJ;
    Oncologist; 2013; 18(7):812-8. PubMed ID: 23814044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study.
    Jackisch C; Kim SB; Semiglazov V; Melichar B; Pivot X; Hillenbach C; Stroyakovskiy D; Lum BL; Elliott R; Weber HA; Ismael G
    Ann Oncol; 2015 Feb; 26(2):320-5. PubMed ID: 25403587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
    Cameron D; Piccart-Gebhart MJ; Gelber RD; Procter M; Goldhirsch A; de Azambuja E; Castro G; Untch M; Smith I; Gianni L; Baselga J; Al-Sakaff N; Lauer S; McFadden E; Leyland-Jones B; Bell R; Dowsett M; Jackisch C;
    Lancet; 2017 Mar; 389(10075):1195-1205. PubMed ID: 28215665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective analysis of efficacy of trastuzumab in adjuvant treatment of HER 2 positive early breast cancer - single institution experience.
    Ban M; Viculin J; Tomic S; Capkun V; Strikic A; Mise BP; Utrobicic I; Vrdoljak E
    Neoplasma; 2016; 63(5):761-7. PubMed ID: 27468880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan.
    Lang HC; Chen HW; Chiou TJ; Chan AL
    J Med Econ; 2016 Oct; 19(10):923-7. PubMed ID: 27135256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
    Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.
    Mates M; Fletcher GG; Freedman OC; Eisen A; Gandhi S; Trudeau ME; Dent SF
    Curr Oncol; 2015 Mar; 22(Suppl 1):S114-22. PubMed ID: 25848335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
    Tolaney SM; Barry WT; Dang CT; Yardley DA; Moy B; Marcom PK; Albain KS; Rugo HS; Ellis M; Shapira I; Wolff AC; Carey LA; Overmoyer BA; Partridge AH; Guo H; Hudis CA; Krop IE; Burstein HJ; Winer EP
    N Engl J Med; 2015 Jan; 372(2):134-41. PubMed ID: 25564897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial.
    Fountzilas G; Dafni U; Papadimitriou C; Timotheadou E; Gogas H; Eleftheraki AG; Xanthakis I; Christodoulou C; Koutras A; Papandreou CN; Papakostas P; Miliaras S; Markopoulos C; Dimitrakakis C; Korantzopoulos P; Karanikiotis C; Bafaloukos D; Kosmidis P; Samantas E; Varthalitis I; Pavlidis N; Pectasides D; Dimopoulos MA
    BMC Cancer; 2014 Jul; 14():515. PubMed ID: 25026897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.